Dave Ahern's avatar
$4.8m follower assets
Revenues of the Top US Producers of Insulin
As I prepare for the next shallow dive focusing on $NVO I am investigating the pharma sector focusing on diabetes and obesity. Below is a chart from Stratosphere highlighting the revenues of the top US producers of insulin.

$LLY sent a shockwave through the insulin producers with their announcement of a cap of prices, while long-overdue, the markets haven't reacted much so maybe its a lot of noise at this point. Will be interesting to see how the others react and the impact to financials.

Image upload
Joshua Simka's avatar
How soon do you think we see GLP-1s like $NVO's Ozempic and Wegovy eclipse insulin as the standard of care for diabetes?
Dave Ahern's avatar
@tomato my guess is sooner than later. There are a few "cures" for diabetes on the horizon in the private sector world which would upend the market completely, but I am not sure at what stage they are in testing. But all of my diabetic friends are all using the Ozempic to help control their diabetes instead of insulin. What I have learned from my own experience, is once you get on insulin its incredibly difficult to get off and I think people are choosing a different path than insulin. I know that's what I did.
Dave Ahern's avatar
@tomato what do you think?
Joshua Simka's avatar
@ifb_podcast I agree with you. As the obesity medicines come into broader use I think we'll see more focus on treating that rather than diabetes (which is an effect of the obesity)



Already have an account?